Revenue
8.54 million Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg
2024 Q3 · Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg
Exact inputs and evidence
- Revenue: 8541000 Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg Source
Fundies. English
MARINUS PHARMACEUTICALS, INC.
EDGAR56 filing records in this dataset, filed from 2014-05-12 to 2024-11-12. Reported financial figures are available; chart coverage varies by period.
Latest quarter
- Cash and cash equivalents
- 42.2 million Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg Source
Exact value
42200000 Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg
- Long-term debt including current maturities
- 56.3 million Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg Source
Exact value
56250000 Unit_Standard_USD_OUN-EYW7F0S0sG2txdMOwg
- Shares outstanding
- 55.2 million Unit_Standard_shares_gcb7jmNYg0SIrfGs2COxBA Source
Exact value
55185622 Unit_Standard_shares_gcb7jmNYg0SIrfGs2COxBA
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2024-11-12.
Financial data available through: 2023-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2023-12-31
- Operating income: 2 of 11 periods available· newest 2023-12-31
- Net income: 2 of 11 periods available· newest 2023-12-31
- Operating cash flow: 2 of 11 periods available· newest 2023-12-31
- Capital expenditure: 2 of 11 periods available· newest 2014-12-31
- Total assets: Multiple units; comparison withheld· newest 2023-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2023-12-31
- Current assets: Multiple units; comparison withheld· newest 2023-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2023-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2023-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2023-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2023-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+21.6%Prior period
Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 25.48 million
–
Current period
Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 30.99 million
–
Exact inputs and evidence
30989000 − 25478000 = 5511000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w
25478000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2022-01-01 – 2022-12-31
Inspect prior input Prior source30989000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2023-01-01 – 2023-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 121.58 millionPrior period
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 19.82 million
–
Current period
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 141.4 million
–
Exact inputs and evidence
-141400000 − -19816000 = -121584000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w
-19816000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-141400000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2023-01-01 – 2023-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 5.12 millionPrior period
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 112.89 million
–
Current period
−Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 118 million
–
Exact inputs and evidence
-118001000 − -112886000 = -5115000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w
-112886000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-118001000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w · 2023-01-01 – 2023-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2023 2023-01-01 – 2023-12-31
- Revenue Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 30.99 million 100% of revenue
- Operating costs Derived Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 162.47 million 524% of revenue
- Operating income −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 131.49 million −424% of revenue
- Tax, interest and other Derived Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 9.92 million 32% of revenue
- Net income −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 141.4 million −456% of revenue
Cash
- Operating cash flow −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 118 million −381% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2022 Operating loss: operating costs were 543% of revenue.
- 2023 Operating loss: operating costs were 524% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | 25478000 | 138266000 Derived | -112788000 | -92972000 Derived | -19816000 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 30989000 | 162474000 Derived | -131485000 | 9915000 Derived | -141400000 | Unavailable | Source
|
Amounts are exact, in Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 31M 2023
Values and sources
| Period | Series | Value(Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w) | Source evidence |
|---|---|---|---|
| 2022 | Revenue | 25478000 |
|
| 2023 | Revenue | 30989000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
21.6% 2023
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | 21.6% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -424.3% 2023
Net margin -456.3% 2023
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Operating margin | -442.7% |
|
| 2023 | Operating margin | -424.3% |
|
| 2022 | Net margin | -77.8% |
|
| 2023 | Net margin | -456.3% |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w -118M 2023
Values and sources
| Period | Series | Value(Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w) | Source evidence |
|---|---|---|---|
| 2022 | Operating cash flow | -112886000 |
|
| 2023 | Operating cash flow | -118001000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w) | Source evidence |
|---|---|---|---|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2023-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2023-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 19.82 million Exact valueExact value: -19816000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 2022-01-01 – 2022-12-31: -19816000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 112.89 million Exact valueExact value: -112886000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 2022-01-01 – 2022-12-31: -112886000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 141.4 million Exact valueExact value: -141400000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 2023-01-01 – 2023-12-31: -141400000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 118 million Exact valueExact value: -118001000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w 2023-01-01 – 2023-12-31: -118001000 Unit_Standard_USD_oOfpOg9HmUuxeJj__j2R2w Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
56 filings · 3,466 latest values · 3,466 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001267813, 1267813, MRNS, edgar:1267813
Also known as MARINUS PHARMACEUTICALS INC, MARINUS PHARMACEUTICALS, INC., MARINUS PHARMACEUTICALS, INC., Marinus Pharmaceuticals, Inc., Marinus Pharmaceuticals, Inc.